| Project/Area Number |
25893136
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Shimane University |
|---|
Principal Investigator |
NAKAYAMA Naomi 島根大学, 医学部, 特別協力研究員 (60713188)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
URANO Takeshi
KATO Hiroaki
|
|---|
| Project Period (FY) |
2013-08-30 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | がん関連転写制御因子 / 膵がん / NAC-1 / NAC1 / 膵癌 / 癌関連転写制御因子 |
|---|
| Outline of Final Research Achievements |
NAC1 is a BTB/POZ-domain transcription factor. It is overexpressed in ovarian serous carcinoma and NAC1 knock-down resulted in the apoptosis of ovarian cancer cell lines and rescued their sensitivity to chemotherapy, suggesting that NAC1 may be a potential therapeutic target. In this study, we elucidated that 1) NAC1 binds DNA through its BEN domain, 2) identification of the consensus DNA-binding sequence of NAC1, and 3) NAC1 forms a nuclear protein complex capable of modulating gene expression with an apparent molecular weight of 350-450 kDa.
To conquer pancreatic cancer, further analysis requires to find out true downstream genes of NAC1.
|
